Table 2.
Pre‐STEMI Statin Eligibility According to ATP III Cholesterol Guidelines
| APT III CHD Risk Categories | ||||||
|---|---|---|---|---|---|---|
| 0 or 1 Risk Factor | 2 Risk Factors | CHD Risk >20% | Diabetes Mellitus | Prevalent CHD | Total | |
| 727 STEMI patients not taking statin therapy prior to STEMI | ||||||
| LDL‐C goal | <160 mg/dL | <130 mg/dL | <100 mg/dL | <100 mg/dL | <100 mg/dL | |
| No. | 65 | 380 | 90 | 79 | 113 | 727 |
| Age, y | 56.9±13.8 | 60.3±12.6 | 68.1±10.8 | 68.0±12.9 | 65.7±13.4 | 62.6±13.2 |
| Women, No. (%) | 29 (44.6) | 103 (27.1) | 4 (4.4) | 34 (43.0) | 25 (22.1) | 195 (26.8) |
| LDL‐C, mg/dL | 109 (86, 137) | 108 (87, 130) | 124 (106, 145) | 95 (72, 118) | 108 (83, 138) | 109 (86, 134) |
| Statin eligible, No. (%) | 5 (7.7) | 96 (25.3) | 75 (83.3) | 37 (46.8) | 68 (60.2) | 281 (38.7) |
| 1062 STEMI patients—estimating off‐treatment LDL‐C levels for those taking statins* | ||||||
| LDL‐C goal | <160 mg/dL | <130 mg/dL | <100 mg/dL | <100 mg/dL | <100 mg/dL | |
| No. | 69 | 454 | 111 | 127 | 301 | 1062 |
| Age, y | 58.0±14.1 | 60.7±12.6 | 67.7±10.9 | 67.0±12.9 | 66.8±12.5 | 63.7±13.0 |
| Women, No. (%) | 30 (43.5) | 132 (29.1) | 4 (3.6) | 54 (42.5) | 72 (23.9) | 292 (27.5) |
| LDL‐C, mg/dL | 107 (86, 136) | 109 (87, 133) | 126 (106, 149) | 99 (74, 121) | 104 (78, 130) | 108 (85, 134) |
| Statin eligible, % | 5 (7.3) | 124 (27.3) | 91 (82.0) | 63 (49.6) | 163 (54.2) | 446 (42.0) |
ATP III indicates Third Report of the Adult Treatment Panel; CHD, coronary heart disease.
*For patients taking statin therapy prior to ST‐segment elevation myocardial infarction (STEMI), a 30% increase in low‐density lipoprotein cholesterol (LDL‐C) was assumed. LDL‐C levels are presented as median (interquartile range).